{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:43:14Z","timestamp":1780544594967,"version":"3.54.1"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"32","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,11]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Sacubitril\/valsartan (Entresto) is the first drug approved for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adult patients. There have been no reports of hepatotoxicity secondary to sacubitril\/valsartan administration. Here, we report the first case of severe liver injury caused by sacubitril\/valsartan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 90-year-old female patient taking sacubitril\/valsartan was admitted due to chronic heart failure. Subsequently, the patient developed serious liver injury with increased hepatic transaminases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>Drug-induced liver injury, sacubitril\/valsartan-related. No liver injury caused by other reasons was observed after thorough examination. After the withdrawal of sacubitril\/valsartan, the liver function of the patient gradually returned to normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>We chose general liver protection methods to improve her hepatic function, including magnesium isoglycyrrhizinate at 100\u2009mg daily and polyene phosphatidylcholine capsules at 456\u2009mg 3 times daily. We consulted with a hepatologist to discuss the best plan for her treatment. The last, we stopped sacubitril\/valsartan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>After the withdrawal of sacubitril\/valsartan, the liver function of the patient gradually returned to normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Sacubitril\/valsartan-induced liver injury is very rare. Clinicians should pay particular attention to the possibility of hepatotoxicity during sacubitril\/valsartan treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000034732","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T14:03:15Z","timestamp":1691762595000},"page":"e34732","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Sacubitril\/valsartan-induced liver injury: A case report and literature review"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5338-6179","authenticated-orcid":false,"given":"Ting","family":"Zhang","sequence":"first","affiliation":[{"name":"Department II of Respiratory and Critical Care in Jiangxi Provincial People\u2019s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-lian","family":"Cai","sequence":"additional","affiliation":[{"name":"Department II of Respiratory and Critical Care in Jiangxi Provincial People\u2019s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8608-7228","authenticated-orcid":false,"given":"Jie","family":"Yu","sequence":"additional","affiliation":[{"name":"Department II of Respiratory and Critical Care in Jiangxi Provincial People\u2019s Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e00794","DOI":"10.1002\/prp2.794","article-title":"Exploring the food and drug administration\u2019s review and approval of entresto (sacubitril\/valsartan).","volume":"9","author":"Eadie","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10741-018-9757-1","article-title":"Practical guidance on the use of sacubitril\/valsartan for heart failure.","volume":"24","author":"Sauer","year":"2019","journal-title":"Heart Fail Rev"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","article-title":"Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.","volume":"42","author":"Jackson","year":"2021","journal-title":"Eur Heart J"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.hlc.2020.08.014","article-title":"Safety and tolerability of sacubitril\/valsartan initiation in inpatient versus outpatient setting: a retrospective real world study.","volume":"30","author":"Chng","year":"2021","journal-title":"Heart Lung Circ"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury.","volume":"5","author":"Andrade","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.drudis.2008.11.009","article-title":"The future of drug safety testing: expanding the view and narrowing the focus.","volume":"14","author":"Stevens","year":"2009","journal-title":"Drug Discov Today"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in Mainland China.","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","article-title":"Combined angiotensin receptor antagonism and neprilysin inhibition.","volume":"133","author":"Hubers","year":"2016","journal-title":"Circulation"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2459\/JCM.0000000000001411","article-title":"Sacubitril\/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis.","volume":"24","author":"Basile","year":"2023","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial.","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/ejhf.1932","article-title":"Looking at the heart failure through the prism of liver dysfunction.","volume":"22","author":"Zymli\u0144ski","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/ejhf.1853","article-title":"Liver function and prognosis, and influence of sacubitril\/valsartan in patients with heart failure with reduced ejection fraction.","volume":"22","author":"Suzuki","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R13-20250504","first-page":"728","article-title":"Pharmacokinetics and safety of sacubitril\/valsartan (LCZ696) in patients with mild and moderate hepatic impairment.","volume":"55","author":"Kulmatycki","year":"2017","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/pharmaceutics12040320","article-title":"Dual angiotensin receptor and neprilysin inhibitor ameliorates portal hypertension in portal hypertensive rats.","volume":"12","author":"Hsu","year":"2020","journal-title":"Pharmaceutics"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2036.2008.03655.x","article-title":"Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.","volume":"27","author":"Garc\u00eda-Cort\u00e9s","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3389\/fphar.2019.00853","article-title":"Roussel uclaf causality assessment method for drug-induced liver injury: present and future.","volume":"10","author":"Danan","year":"2019","journal-title":"Front Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:24:38Z","timestamp":1746325478000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":16,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034732","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}